Why the study?
Does L-158,809 improve cardiac hypertrophy and nephropathy in Tsukuba hypertensive mice?
Population
27 male mice aged 20 weeks
Comparison
L-158,809 administered for 8 weeks vs No dosage and normal control animals
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Does not inform clinical practice; extends preclinical evidence for BP-independent RAS effects on cardiac hypertrophy and nephropathy in mice.
Does L-158,809 improve cardiac hypertrophy and nephropathy in Tsukuba hypertensive mice?
L-158,809 ameliorates cardiac hypertrophy and nephropathy in a hypertensive mouse model independent of blood pressure reduction, highlighting the direct role of the renin-angiotensin system in end-organ damage.
Kai et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: